Ind-Swift Laboratories Ltd
Incorporated in 1995, Ind-Swift Laboratories Ltd is engaged in the manufacturing of Active Pharmaceutical Ingredients(APIs), and Advanced Intermediates, and providing Contract Research and Manufacturing Services (CRAMS). [1]
- Market Cap ₹ 545 Cr.
- Current Price ₹ 92.2
- High / Low ₹ 123 / 54.0
- Stock P/E
- Book Value ₹ 123
- Dividend Yield 0.00 %
- ROCE 13.3 %
- ROE 9.59 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.75 times its book value
Cons
- Company has a low return on equity of 3.20% over last 3 years.
- Promoters have pledged 86.8% of their holding.
- Company has high debtors of 153 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,409 | 1,134 | 965 | 660 | 653 | 716 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | |
1,231 | 1,063 | 906 | 571 | 546 | 610 | 631 | 630 | 635 | 709 | 837 | 978 | |
Operating Profit | 178 | 72 | 59 | 89 | 107 | 106 | 134 | 126 | 144 | 183 | 202 | 229 |
OPM % | 13% | 6% | 6% | 13% | 16% | 15% | 18% | 17% | 19% | 21% | 19% | 19% |
33 | 4 | -19 | -31 | 1 | 15 | 16 | 120 | 33 | 23 | 37 | 7 | |
Interest | 85 | 140 | 117 | 117 | 106 | 88 | 28 | 92 | 107 | 100 | 96 | 92 |
Depreciation | 40 | 54 | 66 | 84 | 85 | 88 | 87 | 104 | 90 | 87 | 131 | 57 |
Profit before tax | 87 | -119 | -142 | -143 | -83 | -55 | 36 | 50 | -20 | 18 | 13 | 87 |
Tax % | -3% | 1% | 14% | 17% | 29% | 29% | 39% | 42% | -7% | 117% | 117% | 45% |
89 | -118 | -122 | -119 | -59 | -39 | 22 | 29 | -21 | -3 | -2 | 48 | |
EPS in Rs | 23.50 | -30.02 | -29.79 | -29.14 | -14.33 | -8.75 | 4.85 | 6.09 | -3.59 | -0.53 | -0.36 | 8.06 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 1% |
5 Years: | 10% |
3 Years: | 16% |
TTM: | 16% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 22% |
3 Years: | 70% |
TTM: | 4632% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 10% |
3 Years: | 12% |
1 Year: | 43% |
Return on Equity | |
---|---|
10 Years: | -3% |
5 Years: | 0% |
3 Years: | 3% |
Last Year: | 10% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 38 | 39 | 41 | 42 | 42 | 45 | 46 | 48 | 60 | 60 | 60 | 60 | 59 |
Reserves | 784 | 814 | 684 | 553 | 476 | 486 | 507 | 540 | 581 | 544 | 541 | 622 | 671 |
1,013 | 1,240 | 1,355 | 1,413 | 1,457 | 1,242 | 1,083 | 1,148 | 1,031 | 1,005 | 953 | 862 | 802 | |
383 | 280 | 258 | 236 | 240 | 364 | 387 | 188 | 198 | 210 | 247 | 280 | 267 | |
Total Liabilities | 2,218 | 2,374 | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,799 |
910 | 1,171 | 1,174 | 1,117 | 1,099 | 1,042 | 934 | 914 | 843 | 753 | 630 | 587 | 570 | |
CWIP | 294 | 161 | 78 | 113 | 78 | 70 | 69 | 20 | 11 | 19 | 10 | 8 | 8 |
Investments | 19 | 17 | 17 | 18 | 18 | 18 | 18 | 19 | 17 | 36 | 29 | 30 | 30 |
995 | 1,025 | 1,070 | 997 | 1,020 | 1,007 | 1,002 | 972 | 998 | 1,011 | 1,131 | 1,199 | 1,191 | |
Total Assets | 2,218 | 2,374 | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,799 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
73 | -47 | 0 | 98 | 79 | 96 | 73 | -64 | 125 | 135 | 150 | 195 | |
-205 | -48 | 0 | -35 | -29 | -31 | -17 | -12 | -9 | -10 | 5 | -13 | |
125 | 66 | 0 | -64 | -48 | -69 | -62 | 100 | -133 | -124 | -141 | -186 | |
Net Cash Flow | -7 | -29 | 0 | -1 | 3 | -4 | -6 | 23 | -17 | 1 | 14 | -4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 79 | 133 | 168 | 215 | 208 | 182 | 194 | 169 | 186 | 177 | 160 | 153 |
Inventory Days | 161 | 180 | 182 | 312 | 368 | 305 | 291 | 284 | 315 | 301 | 288 | 242 |
Days Payable | 83 | 81 | 103 | 120 | 137 | 91 | 118 | 114 | 124 | 111 | 118 | 113 |
Cash Conversion Cycle | 157 | 232 | 247 | 407 | 439 | 396 | 367 | 339 | 377 | 367 | 330 | 282 |
Working Capital Days | 163 | 246 | 277 | 379 | 255 | 110 | 99 | 305 | 313 | 303 | 290 | 267 |
ROCE % | 11% | 2% | 0% | 1% | 2% | 2% | 4% | 4% | 5% | 7% | 7% | 13% |
Documents
Announcements
- Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD 1d
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 2d
- Corrigendum To The Financial Results For The Quarter And Half Year Ended 30Th September, 2023 8 Nov
- Compliances-Reg. 54 - Asset Cover details 7 Nov
- Financial Results For The Quarter And Half Year Ended On 30.09.2023. 7 Nov
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Segments
APIs: The Co. manufactures APIs for complex therapies including Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, etc. [1]
CRAMS: The Co. provides Contract Research and Manufacturing Services supporting R&D programs from process development to clinical supplies. Its capabilities include synthetic medicinal chemistry, custom synthesis, process R&D, cGMP manufacturing, analytical development, and regulatory support. [2]
Research & Development: The Co. has an R&D center primarily focused on the development and optimization of new and existing process technologies supporting the manufacturing of APIs. [2]
Impurities: The Co. has impurities for over 25 APIs. The Co’s impurity portfolio is stocked with a wide range of standards for quick and reliable supply. [3]